和誉-B（02256）近日发布公告，公司董事会已提议对现有名称体系进行调整。根据公告内容，和誉开曼有限责任公司的英文名称将由“Abbisko Cayman Limited”变更为“Abbisko Medicine Co., Ltd.”，同时其中文双重外文名称也将从“和誉开曼有限责任公司”同步更新为“和誉医药有限责任公司”。
此次名称变更提案旨在进一步优化公司品牌形象，并更好地反映其业务发展定位。目前该建议已正式提交，尚待相关程序批准后生效。市场投资者可关注后续公告以获取最新进展。
和誉-B（02256）近日发布公告，公司董事会已提议对现有名称体系进行调整。根据公告内容，和誉开曼有限责任公司的英文名称将由“Abbisko Cayman Limited”变更为“Abbisko Medicine Co., Ltd.”，同时其中文双重外文名称也将从“和誉开曼有限责任公司”同步更新为“和誉医药有限责任公司”。
此次名称变更提案旨在进一步优化公司品牌形象，并更好地反映其业务发展定位。目前该建议已正式提交，尚待相关程序批准后生效。市场投资者可关注后续公告以获取最新进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.